Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha

Neurochem Int. 2001 Nov-Dec;39(5-6):449-57. doi: 10.1016/s0197-0186(01)00052-3.

Abstract

Amyloid deposition within the brains of Alzheimer's Disease patients results in the activation of microglial cells and the induction of a local inflammatory response. The interaction of microglia or monocytes with beta-amyloid (A beta) fibrils elicits the activation a complex tyrosine kinase-based signal transduction cascade leading to stimulation of multiple independent signaling pathways and ultimately to changes in proinflammatory gene expression. The A beta-stimulated expression of proinflammatory genes in myeloid lineage cells is antagonized by the action of a family of ligand-activated nuclear hormone receptors, the peroxisome proliferator-activated receptors (PPARs). We report that THP-1 monocytes express predominantly PPAR gamma isoform and lower levels of PPAR alpha and PPAR delta isoforms. PPAR mRNA levels are not affected by differentiation of the cells into a macrophage phenotype, nor are they altered following exposure to the classical immune stimulus, lipopolysaccharide. Previous studies have found that PPAR gamma agonists act broadly to inhibit inflammatory responses. The present study explored the action of the PPAR alpha isoform and found that PPAR alpha agonists inhibited the A beta-stimulated expression of TNFalpha and IL-6 reporter genes in a dose-dependent manner. Moreover, the PPAR alpha agonist WY14643 inhibited macrophage differentiation and COX-2 gene expression. However, the PPAR alpha agonists failed to inhibit A beta-stimulated elaboration of neurotoxic factors by THP-1 cells. These findings demonstrate that PPAR alpha acts to suppress a diverse array of inflammatory responses in monocytes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amyloid / pharmacology
  • Amyloid beta-Peptides / physiology*
  • Cell Differentiation / drug effects
  • Cell Line
  • Cyclooxygenase 2
  • Humans
  • Inflammation / etiology*
  • Interleukin-6 / antagonists & inhibitors
  • Isoenzymes / metabolism
  • Macrophages / cytology
  • Membrane Proteins*
  • Microglia / physiology
  • Monocytes / cytology
  • Monocytes / physiology
  • Neurotoxins / antagonists & inhibitors
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Protein-Tyrosine Kinases / physiology
  • Receptor for Advanced Glycation End Products
  • Receptors, Cytoplasmic and Nuclear / agonists
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Receptors, Cytoplasmic and Nuclear / physiology*
  • Receptors, Immunologic / physiology
  • Receptors, Lipoprotein*
  • Receptors, Scavenger
  • Scavenger Receptors, Class B
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Transcription Factors / agonists
  • Transcription Factors / metabolism
  • Transcription Factors / physiology*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Interleukin-6
  • Isoenzymes
  • Membrane Proteins
  • Neurotoxins
  • Receptor for Advanced Glycation End Products
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Immunologic
  • Receptors, Lipoprotein
  • Receptors, Scavenger
  • Scarb1 protein, mouse
  • Scavenger Receptors, Class B
  • Transcription Factors
  • Tumor Necrosis Factor-alpha
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Protein-Tyrosine Kinases